We have produced a thermally stable recombinant human type 5 adenoviral vector 5 (AdHu5) through spray drying with three excipient formulations (L-leucine, lactose/trehalose 6 and mannitol/dextran). Spray drying leads to immobilization of the viral vector which is believed 7 to prevent viral protein unfolding, aggregation and inactivation. The spray dried powders were 8 characterized by scanning electron microscopy, differential scanning calorimetry, Karl Fischer 9 titrations, and X-ray diffraction to identify the effects of temperature and atmospheric moisture 10 on the immobilizing matrix. Thermal stability of the viral vector was confirmed in vitro by 11 infection of A549 lung epithelial cells. Mannitol/dextran powders showed the greatest 12 improvement in thermal stability with almost no viral activity loss after storage at 20°C for 90 13 days (0.7 ± 0.3 log TCID 50 ) which is a significant improvement over the current -80 o C storage 14 protocol. Furthermore, viral activity was retained over short term exposure (72 hours) to 15 temperatures as high as 55°C. Conversely, all powders exhibited activity loss when subjected to 16 moisture due to amplified molecular motion of the matrix. Overall, a straightforward method 17 ideal for the production of thermally stable vaccines has been demonstrated through spray drying 18
Introduction 1
Adenovirus-based gene transfer vectors have been increasingly developed as vaccine 2 platforms against both old and newly emerging infections (Lasaro and Wong et al., 2007) . Spray drying is increasingly preferred since its 3 simple requirements facilitate product scalability (Ré, 1998 ) and favorable economics. During 4 spray drying, a pressurized gas is used to disperse a liquid feed into small droplets within a 5 drying chamber. Evaporation of heated aqueous droplets results in precipitation of the dissolved 6 solutes and suspended materials. Current research aimed at improving thermal stability for labile 7 biological materials has shown great success with spray drying vaccines ranging from attenuated Calmette-Guérin vaccine formulation with L-leucine demonstrated a minimal activity loss of 12 approximately 2.0 log after 120 days at 25°C under high moisture protection (Wong et al., 2007) . 13 Alternatively, an antigen-based influenza subunit vaccine stabilized in inulin retained 14 considerable immunogenicity for up to three years of storage at 20°C (Saluja et al., 2010) . The 15 variance in stability among spray dried biological materials emphasizes the need for specific 16 evaluation of each vaccine backbone and excipient combination. 17
Human adenovirus type 5 (AdHu5) has been shown to be an effective vaccine vector for 18 prevention of infectious diseases and has been developed in both liquid buffer and lyophilized 19 forms (Frahm et al., 2012; Smaill et al., 2013) . Current limitations to AdHu5 use stem from pre-20 existing AdHu5 immunity and the lack of a thermally stabilized form. It is estimated that 30 -21 100% of the population, depending on geographical location, have been exposed to AdHu5 and 22 therefore elicit an AdHu5-specific response upon infection (Appaiahgari and Vrati, 2014). The 23 anti-AdHu5 immunity pre-existing in most of the human population poses a potential limitation 1 to the application of AdHu5-vectored vaccines. However, the results from our recent clinical 2 vaccine trial suggest that the potency of AdHu5 vector system is able to diminish the negative 3 effect of a pre-existing immunity (Smaill et al., 2013) . Furthermore, AdHu5 vector is particularly 4 amenable to vaccination via the respiratory mucosal route against lung infectious diseases and 5 the human respiratory tract has been found to have minimal pre-existing anti-AdHu5 immunity 6 (Richardson et al., 2011) . Thus, it is expected for AdHu5-based vaccine to be even more 7 effective when given via the respiratory mucosal route versus a parenteral route. In terms of 8 thermal stability, AdHu5 has yet to be developed into a well-stabilized spray dried form. This 9 work extends the possible applications of AdHu5 as a vaccine by producing a more thermally 10 stable vector through spray drying with well-accepted excipients. More specifically, we have 11 evaluated binary sugar and amino acid formulations consisting of semicrystalline and entirely 12 crystalline excipient matrices to observe the effects of crystallinity and T g on AdHu5 stability. 13
The effects of storage time, temperature and humidity were systematically examined on spray 14 dried vector infectivity for AdHu5, which to the best of our knowledge, has not been reported 15 previously. The purpose of this work is to demonstrate a thermally stable spray dried AdHu5 16 vector and highlight the physical properties necessary for the best stabilization, which can be 17 used to further the field of dry powder vector development. Future developments with these 18 spray dried powders will focus on their use for inhalation and optimizing excipient ratios for 19 better thermal stability of the labile material. The future use of these spray dried powders in 20 inhalable applications is dependent on a suitable safety assessment, as the effects of 21 administration of the studied excipients within this work to the lungs has not been fully 22
established. 23 1

Materials and Methods 2
Chemicals and Adenoviral Vectors 3
Anhydrous lactose, D-(+)-trehalose dihydrate, D-mannitol, dextran (M r 40000 kDa) and 4 L-leucine were all purchased as USP grades from Sigma-Aldrich (Ontario, Canada). Culture 5 media was produced from α-minimum essential medium (prepared in the lab according to 6 protocol by Life Technologies (Ontario, Canada)) with 10% fetal bovine serum and 1% 7 streptomycin/penicillin (Invitrogen; Ontario, Canada). X-Gal stock solution was purchased from 8 EMD Millipore (Ontario, Canada). A recombinant replication-defective human type 5 9 adenovirus expressing Escherichia coli β-galactosidase (AdHu5LacZ) was produced in the 10 vector facility of McMaster Immunology Research Centre as described previously (Xing et al., 11 1996) . 12
13
Spray Drying 14
Spray dried powders were produced using a Büchi Mini Spray Dryer B-290 (Büchi; 15 Switzerland) with 0.7 mm spray nozzle and high performance cyclone. The setup is shown 16 schematically in Figure 1 , consisting of 1) the spray drying nozzle, 2) the drying chamber, 3) the 17 separating cyclone and 4) the collection chamber. The atomizing air was dried using an in-line 18 silica gel desiccant air dryer (McMaster-Carr; Elmhurst, IL) and cleaned using an Aervent® 0.2 19 µm filter (EMD Millipore; Billerica, MA). Three excipient formulations were produced: (1) L-20 leucine, (2) 90% lactose and 10% trehalose and (3) 67% mannitol and 33% dextran (all 21 compositions are quoted based on percent by weight). Excipient formulations were dissolved in 22
Milli-Q® water. The AdHu5 vector was stored in a PBS buffer; however, its addition to the 23 excipient solution was negligible, being less than 1/10000 th of the spray dried volume. The input 1 concentration of viral vector for each formulation was 7.56 x 10 6 TCID 50 /mg. The pH of the 2 solution was 6.5. The formulations used within this work were selected from a number of 3 excipients that have been employed within the pharmaceutical and spray drying industry ( Table 1 , in terms of excipients used and excipient ratio) were derived from preliminary spray 7 drying experiments (results not included) that looked to achieve a high yield of non-8 agglomerating particles with matrices of significant amorphous content and high glass transition 9
temperatures. The specific spray dryer conditions used for each formulation were based on those 10 preliminary experiments attempting to minimize the adenoviral vector activity loss through 11 processing. Recovery was calculated as a percentage of the mass of powder in the collection 12 vessel compared to the input amount. All spray drying processes and powder collection were 13 performed in a custom biosafety cabinet (Design Filtration; Ontario, Canada). 14 
20
Sample Storage 21
Powder samples were stored for different durations at relative humidities (RH) of <10%, 22 45% and >90%. Storage humidity was produced with gel desiccants and saturated salt solutions 23 (potassium carbonate, 45% RH; potassium nitrate, >90% RH) within desiccators. The relative 1 humidity within each compartment was confirmed before sample observation through direct 2 measurement with a Fisher Scientific™ Traceable™ Jumbo Thermo-Humidity Meter (Fisher 3 Scientific; Ontario, Canada), and found to vary ±3%. The liquid control containing only buffer 4 and AdHu5LacZ was stored in a tightly sealed vial under ambient conditions due to the 5 dehydrating effects of desiccants and saturated salts, though it is assumed that humidity would 6 have no effect on the liquid sample. All aging trials examining the influence of humidity were 7 performed at 20°C. Samples and storage conditions are listed in Table 2 . Sealed samples were 8 stored in closed 2 mL Nalgene General Long-Term Storage Cryogenic Tubes (Nalgene; Ontario, 9 Canada). 10 11 He-Ne laser was used to measure particle size and size distribution. Powder formulations were 8 dispersed in anhydrous ethanol at concentrations of 0.3 mg/mL, 1.0 mg/mL and 1.0 mg/mL for 9 L-leucine, lactose/trehalose and mannitol/dextran formulations, respectively. Mean powder 10 particle size was determined as the average diameter (n=3), and represented as Feret diameters as 11 powders are not entirely spherical. Powder size span was calculated using Equation 1, where 12 D(0.9) represents the diameter greater than 90% of measured particles, D(0.1) represents the 13 diameter greater than 10% of measured particles and D(0.5) represents the median diameter. 14
15
X-ray Photoelectron Spectroscopy 16
Surface elemental analysis was performed using a Physical Electronics (PHI) Quantera II 17 X-ray photo electron spectrometer (Physical Electronics; Chanhassen, MI). Samples containing 18 adenoviral vectors were inactivated through exposure to UV light for 30 minutes. X-rays were 19 generated using an Al source and focused with a quartz crystal monochromator. A 20 monochromatic Al K-α X-ray (1486.7 eV) source was operated at 50W 15kV with a spot size of 21 200 µm and at pressures less than 2.67 x 10 -6 Pa. Each recorded measurement was a survey 22 spectra average of five sample scans. Data manipulation and analysis was performed using PHI 1
MultiPak software (Physical Electronics; Chanhassen, MI). Titrator (Mettler Toledo; Columbus, OH). The corresponding water content was determined 10 using Equation 2: 11
where x was the measured water content of the sample after Karl Fischer titration (ppm), and f1 12 was the water content of the solvent used (ppm). Water content of the formamide solvent was 13 measured by adding formamide without dissolved solids to the Karl Fischer titrator. f2 was the 14 measured mass of solvent (g) and f3 represents the mass of dissolved sample (g). 15 16
Thermal Properties of the Spray Dried Particles 17
Thermograms for the three excipient formulations (without adenoviral vector) were 18 measured using a differential scanning calorimeter (DSC). Samples of 3-10 mg were weighed 19 into hermetically sealed aluminum pans for analysis in a Q200 Differential Scanning Calorimeter 20 (TA Instruments; New Castle, DE). The procedure for measurement involved first equilibrating 21 the sample at 4°C. Sample was heated to 300°C at a ramp rate of 10°C/min under a nitrogen 22 purge gas flowing at 50 mL/min. The heating rate was established from a previous study 1 characterizing lactose and trehalose samples (Mazzobre et al., 2001 ). Thermal events were 2 recorded from a single heating ramp to avoid dehydration of the sample. 3 4
Crystallinity of Spray Dried Particles 5
The excipient formulations (without adenoviral vector) were characterized by powder X-6 ray diffraction (XRD) on a Bruker D8 Discover with DAVINCI.DESIGN difractometer (Bruker; 7 Billerica, MA) using a Cobalt Sealed Tube Source (λ avg = 1.79026 Å, 2Ө = 5-70°). Small sample 8 quantities were mounted on a silica base for examination. A blank silica sample signal was 9 subtracted from each measured data set using GADDS software (Bruker; Billerica, MA), and the 10 resulting signal intensity was integrated into a crystallographic figure through the use of 11 DIFFRAC.EVA software (Bruker; Billerica, MA). Crystalline content was determined using 12 TOPAS software (Bruker; Billerica, MA). 
Data Analysis 7
Where applicable, results were statistically analyzed using the statistical package R (R 8
Foundation for Statistical Computing; Austria). Results were considered statistically significant 9 for p ≤ 0.05. 10 
11
Results and Discussion 12
Characterization of Spray Dried Powders without Adenoviral Vector 13
Size and Morphology 14
The spray dried powder formulations were imaged by SEM at varying magnifications to 15 evaluate size and morphology, as shown in Figure 2 . L-leucine particles were generally less than 16 10 µm in diameter (Figures 2a and 2b) , with an average of 8.80 µm ( Table 3 ). The size 17 distribution was broadest for L-leucine compared to the other formulations and had a noted 18 skewness in the Mastersizer favoring smaller particles. These particles had a "collapsed sphere" Average particle diameter for the lactose/trehalose and mannitol/dextran powders were 32.2 µm 3 and 7.92 µm, respectively ( Table 3 ). The larger average particle size for the lactose/trehalose 4 formulation can be attributed to a greater amount of agglomeration between developed particles 5 (notable by the bridging outlined in Figures 2c and 2d) . The span in the size distribution for these 6 two formulations were smaller, as indicated in Table 3 , compared to L-leucine and both showed 7 a more normal distribution of sizes according to the Mastersizer around their means. 8 
11
Moisture Uptake 12
The measured water content after storage under different humidity conditions is plotted in 13 Figure 3 for the three spray dried formulations. For the 15 day evaluation, the least hygroscopic 14 spray dried powder was produced with the L-leucine formulation. Total moisture content for L-15 leucine (measured as percent weight of the total) was 0.98%, 1.98% and 6.76% under controlled 16 relative humidity conditions of <10, 45 and >90% RH, respectively. In comparison, the 17 lactose/trehalose formulation absorbed significant amounts of water, measured as 2.54%, 4.21% 18 and 17.08% for <10, 45, and >90% RH, respectively. A similar amount of moisture uptake was 19 determined for the mannitol/dextran formulation; at <10, 45, and >90% RH, the respective 15 20 day measurements were 1.72%, 5.89% and 15.05%. 21
Many pharmaceutically relevant excipients have hydrogen bonding potential, allowing 1 for the binding of water from their surrounding environment (Newman et al., 2008) . The 2 absorption of water within solid dispersions is generally deleterious, destabilizing their physical 3 structure by depressing the T g and inducing changes within the crystalline structure. As a result, 4 minimal moisture uptake is optimal for the dispersed active ingredient to remain immobilized for 5 as long as possible (Ahlneck and Zografi, 1990; Hancock and Zografi, 1994) . The low water 6 sorption capacity of L-leucine particles is due to the high crystalline content Both lactose and 7 trehalose are considered to be highly hygroscopic materials and hence, it was not unexpected that 8 the spray dried particles from these ingredients similarly showed high moisture uptake in the 9 experiments. Mannitol is typically crystalline and non-hygroscopic (Naini et al., 1998 ), yet the 10 inclusion of dextran produced spray dried particles with high moisture sensitivity. 11
All spray dried powders showed no significant change in moisture content after day 1 12 when stored at 45% RH or less. In comparison, when stored at >90% RH the powders continued 13 to uptake water and showed no evidence of approaching an equilibrium condition within the 14 tested 15 day period. The spray dried powders stored at >90% RH proved too difficult to 15 preserve in their current state for the detailed characterizations that follow that they will not be 16 reported on further. These powders agglomerated into large masses and were very sticky, 17
proving to be difficult to work with and unsuitable for AdHu5 stabilization. 18
19
Crystallinity 20
The three spray dried powders were analyzed by X-ray diffraction as shown in Figure 4 . 21
The crystal structure differences were attributed to the different chemical composition of each 22 formulation. Measured crystalline content is shown in Table 4 for each formulation immediately 23 after spray drying. The crystallinity for L-leucine was very high, as the particle was mostly 1 crystallized. Both lactose/trehalose and mannitol/dextran formulations were measured to be 2 semicrystalline. 3 Table 4 . Measured crystallinity for all formulations immediately after spray drying. and 45% RH, a small amount of peak broadening was observed for L-leucine. This broadening 10 corresponds with a marginal increase in water content at these conditions, suggesting absorbed 11 water may have partially dissolved and/or disrupted the L-leucine crystal structure. 12
The diffraction patterns in Figure 4b for the lactose/trehalose formulation displayed 13 crystalline α-lactose monohydrate peaks as well as a large amorphous band, when powders were 14 tested immediately after spray drying. The absence of diffraction peaks for α,α-trehalose 15 dehydrate was unexpected due to its high crystallizing nature and from the fact that its crystalline 16 form has been reported after freeze drying (Sundaramurthi and Suryanarayanan, 2010) 
but in this 17
case its low concentration likely prevented detection by XRD. The significant amorphous 18 content shown was expected having been previously reported for spray dried lactose (Lerk, 19 1993 ) and furthermore, blends of lactose and trehalose are known to inhibit crystallization in the 20 complementary component (Miao and Roos, 2005) . It has been previously reported that the 21 presence of trehalose in a lactose system delayed and prevented lactose crystallization through 22 interference of growth of the crystal lattice (Mazzobre et al., 2001) . After storage at 20°C for two 1 weeks, the crystalline regions were less apparent by XRD, even at low humidity. The work of 2 other authors has demonstrated that the onset of crystallization for lactose and trehalose blends 3 occur at 65.6% RH (Miao and Roos, 2005) , 1996) . This effect of dehydration on 8 crystal structures has been previously reported under mild conditions for both raffinose-and Overall, the presence of moisture is detrimental to the structural stability of the matrix as 3 seen by changes in crystal structure for all three excipient formulations. These changes in crystal 4 structure are indicative of movements on the molecular scale, which correspond to activity loss 5 in spray dried particles containing adenoviral vectors, as discussed further below. 6 7
Thermal Properties 8
The thermal transitions of spray dried particles from each of the three formulations were 9
analyzed by DSC. The glass transition temperature and peak fusion/sublimation temperature (T m ) 10 are given in Table 5 . Spray dried L-leucine particles had sufficiently high crystallinity that the 11 glass transition temperature could not be detected. An endothermic peak at 247°C corresponded 12 After storage for two weeks at 20°C and under dry conditions (<10% RH), the 19 lactose/trehalose and mannitol/dextran powder T g did not change noticeably, as shown in Table  20 4. However, after storage for two weeks at 20°C and intermediate humidity conditions (45% 21 RH), the T g for lactose/trehalose and mannitol/dextran decreased significantly to 15°C and 45°Crespectively. The decrease in measured T g is caused by the plasticizing effect of absorbed water 1
(Hancock and Zografi, 1994). 2
The T m and especially T g were key parameters in determining matrix stability in terms of 3 immobility. Simply stated, higher T g and T m were preferred due to the higher ambient 4 temperatures necessary to induce destabilizing molecular movement 5 
9
Effect of Excipient Formulations on In Vitro Experiments 10
To ensure accurate viral infection measurements, the base spray dried formulations 11 without adenoviral vector were tested for their relative toxicity to the plated A549 cells. The 12 powders were tested at a concentration level that was three times higher than that for later in 13 vitro testing. Cell viability corresponding to each formulation is shown in Table 6 . No 14 cytotoxicity was observed for the three formulations based on the absence of any significant 15 differences in cell viability between the formulations and the control (α-MEM). 16 17 
20
Evaluation of Spray Dried Particles Containing Adenoviral Vector 21
Retained Viral Activity After Spray Drying 1
Spray dried powders containing human type 5 adenoviral vector expressing Escherichia 2 coli β-galactosidase (AdHu5LacZ) were prepared and were indistinguishable in initial 3 appearance from the powders without the viral vector. The high temperatures and shear rates 4 experienced during the spray drying process could presumably lead to some loss in viral 5 infectivity and as such, the vector activity for each formulation was tested immediately after 6 spray drying. As shown in Figure 5 , while the L-leucine formulation resulted in a relatively large 7 loss in activity (2.6 ± 0.5 log), the lactose/trehalose and mannitol/dextran formulations exhibited 8 excellent retention of adenoviral vector infectivity with less than 1.0 log loss. The activity loss 9 for spray dried mannitol/dextran with AdHu5 particles was the smallest within this report, being 10 only 0.3 ± 0.1 log. For all three formulations, the collected powder recovery after spray drying 11 was greater than 80% (Table 1) which was important because it implied an efficient processing 12 method where there was no significant loss of valuable biological material, such as the 13 AdHu5LacZ vector tested here. 14 SEM micrographs of spray dried particles containing the adenoviral vector are shown in 15 Separation could occur due to the high Peclet conditions of L-leucine during spray drying and 23 the "expelling" nature of forming crystals. Due to the low solubility of L-leucine molecules, 1 supersaturation at the droplet surface is thought to occur early in the drying process (Vehring et 2 al., 2007) . Furthermore, a crystalline material is unlikely to form stabilizing bonds with any other 3 material, as it is instead more favourable to continue the crystal structure without faults (Jackson, 4 1984 ). The coupling of high Peclet conditions and poor labile material stabilization in a 5 crystalline product explains the greater loss of AdHu5 activity after spray drying with L-leucine. 6
In Figure 6b , the addition of the adenoviral vector to the spray dried lactose/trehalose 7 formulation also resulted in nodules on the particle surface, although these nodules were 330 ± 8 90 nm in diameter, much larger than the AdHu5 vector. These nodules, which were not seen in 9 To improve confidence as to the source of the nodule morphology, the surface 16 characterization technique XPS was used to detect nitrogen as a marker for AdHu5LacZ because 17 this element is not present in lactose, trehalose, mannitol or dextran. Testing by this technique 18
was not done with L-leucine since no element could be identified as a unique marker in this case. 19
The adenoviral vector was unlikely to be solely localized in the nodules but the presence of the 20 nodules suggested closer proximity to the particle surface if they did in fact contain AdHu5LacZ. 21
Nitrogen was detected once out of three tests at the surface of the lactose/trehalose particles and 22 once again out of five tests after argon etching away a surface layer of 100 nm in thickness. The 23 same number of tests were conducted with mannitol/dextran particles, with nitrogen never being 1 detected. The surface elemental composition for a selected test of the AdHu5LacZ control and 2 both lactose/trehalose and mannitol/dextran powders is shown in Table 7 . Due to the detection 3 threshold of the XPS instrument, a concentration of the AdHu5 vector along the tested surface is 4 necessary for nitrogen to be shown in the result. As this is not always the case, it is at times not 5 possible to detect nitrogen. We propose that this method of surface detection for AdHu5 is not 6 entirely concrete, however it offers a valuable insight into potentially observing viral vector 7 locations on formed particles. More confident results with higher resolution could be attained 8 through more rigorous testing, but this would require significant time and resources and is 9 outside the scope of this project. However, the description of the nodules as containing 10
AdHu5LacZ seems compelling based on these SEM and XPS results, and provides a reasonable 11 explanation, in part, for the differences in thermal stability noted between these three excipient 12 formulations. 13 14 Table 7 . Elemental composition by XPS for lactose/trehalose and mannitol/dextran samples 15 (n=8) before and after argon etching 100 nm into the sample. 16 
19
To highlight the fact that the presence of nodules indicating poorly incorporated AdHu5 20 can only be part of the explanation for the differences in thermal stability seen in the tests, the 21 measured viral infectivity loss of only 0.7 ± 0.1 log for the lactose/trehalose formulation needed 22 to be reiterated. The greater activity retained with this formulation compared to L-leucine is 23 attributed to the exceptional stabilizing profile of trehalose with other bioactive compounds 1 (Mazzobre et al., 1997) . The total encapsulation of AdHu5LacZ in mannitol/dextran powders is 2 correlated to the low activity loss after spray drying. As described previously, particle formation 3 is affected by diffusion of the excipient components in aqueous solution during spray drying. 4
Dextran diffusion is heavily restricted compared to lactose and trehalose, which are much 5 smaller sugars (Uedaira and Uedaira, 1985) . Thus precipitation at the droplet surface likely 6 begins with dextran, providing less opportunity for adenovirus segregation to the outer particle 7 surface. These results highlight that the chemical nature of the excipients plays a role in their 8 ability to trap and stabilize AdHu5 vector and that morphological inspection of spray dried 9 particles offers further insight into the ability of some formulations to maintain viral infectivity 10 better than others. formulation was able to retain higher viral activity than the other formulations at day 90 for the 21 low humidity condition (p<0.01). The measured AdHu5 titre loss at day 90 was 0.7 ± 0.3 log 22
with mannitol/dextran-formulated vector, only slightly higher than the 0.3 ± 0.1 log measured 23 directly after spray drying. Adenoviral vectors stabilized within lactose/trehalose did not 1 maintain the same degree of function as those stabilized within mannitol/dextran. After 90 days, 2 the measured loss of infectivity for these samples was measured at 3.1 ± 0.3 log. Similarly, L-3 leucine exhibited poor excipient stability as the measured activity loss on day 90 was 4.0 ± 0.2 4 log. For all formulations, the vector activity loss was greatest within the first two weeks. This 5 was likely due to the greater amount of molecular movements within the particle as it 6 transitioned to an equilibrated state post-spray drying. 7 Figure 8 shows the loss of AdHu5LacZ infectivity for each spray dried formulation 8 during storage for up to 90 days at 20°C under moderate moisture conditions (45% RH). By day 9 90, all formulations were considered to be inactive. This represents a significantly greater viral 10 activity loss at 45% RH compared to <10% RH (noted above) which is attributed to the uptake of 11 water by the spray dried powders within the enclosed storage system. Hygroscopic sugars, and 12 even non-hygroscopic L-leucine particles, will take up detectable quantities of water from the 13 humid air (as demonstrated in Figure 3 ). As measured by XRD, the crystallographic profiles for 14 both lactose/trehalose and mannitol/dextran powders showed increasing disorder with water 15 uptake over time. XRD peaks from L-leucine particles exhibited only slight broadening 16 indicating disruption of the initially crystalline spray dried structure. Matrix destabilization was 17 further emphasized by the decrease in T g observed for lactose/trehalose and mannitol/dextran 18 samples (Table 5 ). This significant decrease in T g indicated a greater molecular mobility within 19 the stored samples. Overall, the increase in moisture resulted in an accelerated rate of viral titre 20 loss. Whereas in drier conditions the rate of titre loss leveled off after approximately ten days 21 (referring to Figure 7) , the same is not observed at 45% RH. This emphasizes the need to store 22 potential AdHu5 vaccines in low humidity environments, however this is more easily maintained 23 than -80°C temperatures and can be done, for example, using blister packs which are common 1 practice in the pharmaceutical industry. 2
Overall, the best-performing powder throughout the storage tests was mannitol/dextran 3 which also encapsulated the adenoviral vector without producing nodules after spray drying (as 4 measured by SEM and XPS). The high T g for lactose/trehalose particles implied a great thermal 5 stability should have been expected but this was not observed. This could best be explained 6 through the excipient matrix instability as observed through XRD (Figure 4b ). The glass-like 7 state is known to be thermodynamically unfavourable as the polymer glass is being held with a 8 higher volume and entropy than its equilibrium state (Farhoodi et al., 2012; Struik, 1977) . 9
Physical aging of amorphous and semicrystalline materials can potentially cause a slow 10 relaxation to a more thermodynamically favourable state, even at temperatures below the glass 11 transition (Struik, 1977) . This change occurs more significantly in lactose/trehalose particles than 12 mannitol/dextran particles. These molecular movements result in a greater loss of adenoviral 13 vector function throughout storage. Although similar instability is not observed for L-leucine 14 through XRD, a failure to properly incorporate the AdHu5LacZ vector within the matrix renders 15 it a poor excipient formulation for long term storage. 16 
17
Viral Infectivity at Elevated Temperatures 18
Generally, the mannitol/dextran formulation outperformed the other excipients in its 19 ability to retain adenoviral vector activity under mild storage conditions. This formulation was 20 thus subsequently used to test the thermal stability of AdHu5LacZ at more extreme temperatures 21 of 37°C, 45°C and 55°C. As shown in Figure 9 , spray drying adenoviral vector with the 22 mannitol/dextran formulation was found to thermally stabilize the virus significantly more than 23 the liquid control after 72 hours of storage at increased temperatures (p<0.05). For the liquid 1 control, there was no measurable AdHu5LacZ activity after 30 minutes at 45°C, or for any 2 harsher storage conditions. In contrast, the mannitol/dextran formulation exhibited good activity 3 after 72 hours at both 37°C and 45°C. Only at a storage temperature of 55°C was there a 4 significant loss of viral infectivity after 72 hours for the mannitol/dextran particles. This was due 5 to the increase in energy within the system, which promotes viral protein unfolding (Pace and 6 Hermans, 1975; Pace and Vanderburg, 1979 ). This effect is more pronounced in liquid control 7 samples because there is more molecular movement possible. It is presumed from these results 8 that the mannitol/dextran matrix sufficiently restricts the molecular-scale movements of 9
AdHu5LacZ through immobilization within the vitrified particle, as seen previously for dried 10 influenza viral vaccines (Amorij et al., 2008) . 11
12
Conclusions 13
In conclusion, this work has demonstrated that spray drying is able to produce a high 14 yield of powders capable of incorporating AdHu5 vectors in amino acid or sugar matrices. These 15 matrices allow for an increase in viral vector infectivity, compared to the liquid control, even 16 when the powders are stored at high temperatures. Thermal stability is influenced by particle 17 morphology; amorphous structures can form secondary bonds with the viral vector leading to 18 immobilization which prevents protein unfolding and aggregation. While some degree of matrix 19 crystallinity can aid in avoiding moisture uptake, which in turn restricts both molecular 20 rearrangements and decreasing T g , highly crystalline excipients exhibited viral nodules on the 21 spray dried particle surface and a subsequent decrease in viral activity. The significant loss of 22 viral vector activity in highly crystalline matrices can be avoided through incorporation of a 1 semicrystalline structure, where amorphous content is able to stabilize the AdHu5 vector. 2 Improved thermal stability is most pronounced with mannitol/dextran formulations, 3
where the viral vector was fully encapsulated by the matrix and the semicrystalline morphology 4 remained relatively constant over mild storage conditions. More specifically, particles containing 5
AdHu5 and mannitol/dextran are considered almost fully active after storage for 90 days at 20°C 6 with less than 10% RH, as well as after short term storage at extreme temperatures (stable for 72 7 hours at 45°C and 24 hours at 55°C). This represents a substantial improvement in thermal 8 stability compared to AdHu5 stored in a liquid buffer matrix. are within the range of production capacity by using our best currently developed spray drying 15 technology. Furthermore, an increased initial concentration of AdHu5 in each formulation can be 16 explored through future studies. Overall a processing method and matrix formulation were 17 developed to allow AdHu5-based vaccines to be stored above typical cold chain temperatures, 18 making their deployment more straightforward and at a fraction of the cost compared to current 19 viral storage methods. However, relative humidities above 45% were detrimental to maintaining 20 viral activity due to moisture uptake and increased mobility of the matrix. As a result, spray dried 21 particles with adenoviral vectors should be stored in low humidity conditions using dry 22 packaging examples already existent in the industry (Rubio et al., 2008 (Rubio et al., , 2006 
